Company NuCana plc

Equities

NCNA

US67022C2052

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 03:58:00 2024-07-12 pm EDT			5-day change	1st Jan Change
3.15 ^USD	+1.61%		+12.64%	-57.40%

05:20pm	European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	MT
Jul. 10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	MT

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3â-deoxyadenosine (3â-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Companyâs subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Number of employees: 27

Managers	Title	Age	Since
Hugh Griffith FOU	Founder	56	97-01-27
Donald Munoz DFI	Director of Finance/CFO	56	15-09-30
Michelle Myers CTO	Chief Tech/Sci/R&D Officer	-	-
Elisabeth Oelmann CTO	Chief Tech/Sci/R&D Officer	-	20-08-31
Theresa Margaret Bruce CTO	Chief Tech/Sci/R&D Officer	60	-
Jeffrey Bloss CTO	Chief Tech/Sci/R&D Officer	68	21-08-09
John-Paul Gallivan PRN	Corporate Officer/Principal	-	-
Martin Alexander Quinn SEC	Corporate Secretary	-	17-08-28
Stuart Grant LAW	General Counsel	-	18-08-31

Members of the board	Title	Age	Since
Hugh Griffith FOU	Founder	56	97-01-27
Andrew Kay CHM	Chairman	69	20-12-20
Adam George BRD	Director/Board Member	54	18-04-03
Martin Mellish BRD	Director/Board Member	66	09-12-13
Bali Muralidhar BRD	Director/Board Member	44	20-10-12
Elliott Levy BRD	Director/Board Member	65	21-10-31
Cyrille Leperlier BRD	Director/Board Member	70	18-04-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	52,860,000	51,658,179 ( 97.73 %)	0	97.73 %

Name	Equities	%	Valuation
Sofinnova Investments, Inc. 6.433 %	136,030	6.433 %	346 877 $
Abingworth LLP 6.306 %	133,333	6.306 %	339 999 $
Acadian Asset Management LLC 1.117 %	23,626	1.117 %	60 246 $
Renaissance Technologies LLC 0.7957 %	16,825	0.7957 %	42 904 $
Citadel Securities GP LLC 0.1690 %	3,574	0.1690 %	9 114 $
HRT Financial LLC 0.0632 %	1,337	0.0632 %	3 409 $
Edmond de Rothschild (Suisse) SA 0.0473 %	1,000	0.0473 %	2 550 $
Horizon Kinetics Asset Management LLC 0.0368 %	779	0.0368 %	1 986 $
Geode Capital Management LLC 0.0355 %	751	0.0355 %	1 915 $
G1 Execution Services LLC 0.0268 %	566	0.0268 %	1 443 $

Name	Equities	%	Valuation
Sofinnova Partners SAS 15.65 %	4,978,993	15.65 %	1 M $
Sofinnova Investments, Inc. 4.111 %	1,307,875	4.111 %	340 048 $
Hugh Griffith 3.977 %	1,265,026	3.977 %	328 907 $
Donald Munoz 0.4865 %	154,760	0.4865 %	40 238 $
James Healy 0.2555 %	81,262	0.2555 %	21 128 $
Martin Mellish 0.0879 %	27,952	0.0879 %	7 268 $
Elliott Levy 0.0147 %	4,688	0.0147 %	1 219 $
Bali Muralidhar 0.001698 %	540	0.001698 %	140 $
Jeffrey Bloss 0.000314 %	100	0.000314 %	26 $
Adam George 0.000000 %	0	0.000000 %	- $

NuCana Plc

3 Lochside Way

EH12 9DT, Edinburgh

+44 13 1357 1111

http://www.nucana.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.1 USD

Average target price

209 USD

Spread / Average Target

+6,641.94%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NUCANA PLC	-57.40%	6.96M
VERTEX PHARMACEUTICALS INCORPORATED	+20.11%	127B
REGENERON PHARMACEUTICALS, INC.	+25.23%	117B
ARGENX SE	+25.56%	27.77B
BIONTECH SE	-19.56%	20.44B
GENMAB A/S	-14.36%	16.62B
BEIGENE, LTD.	-15.41%	15.92B
WUXI APPTEC CO., LTD.	-46.67%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+11.95%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.63%	14.38B

Bio Therapeutic Drugs